The Broad Institute’s Cancer Dependency Map Project revealed in their CRISPR and RNAi data sets that 21 of 29 breast cancer cell lines have a dependency score <0 for DDI2, indicating a pro-cancer role for DDI2 in these samples and furthering the hypothesis that inhibition of DDI2 as a single agent could have an anti-tumor effect in certain cancers. The gene discussed is DDI2; the disease is cancer.